Navigation Links
Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Date:5/21/2008

nefits.

Investor Q&A Session

United Therapeutics will host an investor Q&A session following the conclusion of the ATS conference at The Westin Harbour Castle, One Harbour Square, Toronto, Ontario, on May 21, 2008, at 5:00 pm EDT. Vallerie McLaughlin, MD, Director of the Pulmonary Hypertension Program at the University of Michigan, will join United Therapeutics' senior management in this Q&A session, which is also being webcast and can be accessed via United Therapeutics' website at http://ir.unither.com/events.cfm.

About Remodulin

Remodulin is indicated for the treatment of PAH in patients with NYHA Class II-IV symptoms to diminish symptoms associated with exercise. It may be administered as a continuous subcutaneous infusion or continuous intravenous infusion; however, because of the risks associated with chronic indwelling central venous catheters, including serious blood stream infections, continuous intravenous infusion should be reserved for patients who are intolerant of the subcutaneous route, or in whom these risks are considered warranted.

Remodulin is indicated to diminish the rate of clinical deterioration in patients requiring transition from Flolan(R); the risks and benefits of each drug should be carefully considered prior to transition.

Important Safety Information

Chronic intravenous infusions of Remodulin are delivered using an indwelling central venous catheter. This route is associated with the risk of blood stream infections (BSI) and sepsis, which may be fatal. Remodulin is contraindicated in patients with hypersensitivity to Remodulin, its ingredients, or similar drugs. Remodulin is a potent vasodilator. It lowers blood pressure, which may be further lowered by other drugs that also reduce blood pressure. Remodulin inhibits platelet aggregation and therefore, may increase the risk of bleeding, particularly in patients on anticoagulants
'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
2. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
3. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
4. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
5. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
6. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
7. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
10. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
11. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 Apnea Sciences ( www.apneasciences.com ) announced ... Aliso Viejo , California.  Jimmy Fallon ... growth and worldwide expansion, a new facility with expanded ... anti snore cure have exceeded our expectations and thus ... now in 23 countries and will be increasing to ...
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah Associates ... providing a summary of the 2015 marketplace exchange ... trends.  According to a recent ... and Evaluation, Department of Health and Human Services) ... in individual medical plans through the Marketplace as ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2
... Radiation Therapy Services Holdings, Inc. (the “Company”), a ... for the first quarter ended March 31, 2011. ... million, an increase of 16.4% compared to $134.5 million in ... revenue was principally due to revenue from the May 2010 ...
... EDGE, N.J., May 11, 2011 Nephros, Inc. (OTC ... company developing and marketing filtration products for therapeutic applications, ... May 10, 2011 the Company received approval from the ... regulatory agency, to market its Dual Stage Ultrafilters (DSU) ...
Cached Medicine Technology:Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 2Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 3Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 4Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 5Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 6Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 7Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 8Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 9Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 10Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 11Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 2Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 3Nephros Receives Approval to Market Dual Stage Ultrafilters in Canada 4
(Date:12/22/2014)... Physicians in China are most eagerly awaiting ... non-Hodgkin’s lymphoma (NHL), according to a new report from ... firm. MabThera is the only biologic available to treat ... of NHL. , According to Kantar Health’s report, “Biosimilars ... NHL in China has been growing and is expected ...
(Date:12/22/2014)... Only weeks following the announcement that ... to have a battery manufacturer create 29 well-paying jobs ... ) is launching in Henderson to deliver yet ... strong manufacturing sector is going to build a stronger ... “and TalkLocal works with small businesses that rely on ...
(Date:12/22/2014)... Pasadena, CA (PRWEB) December 22, 2014 ... is now offering consultations for sleep apnea. Drowsy drivers ... crashes than drivers who are well-rested, and some experts ... on the roads as intoxicated drivers. Unfortunately, millions of ... to the American Academy of Sleep Medicine, about 18 ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley once again joined ... logistics and support for one of Dallas’ largest holiday toy ... of giving back to the community in which it lives ... were Whataburger® and 99.5 The Wolf. , There is no ... to children who would otherwise not receive any is a ...
(Date:12/22/2014)... 21, 2014 A substantial percentage ... computed tomography (CT) to evaluate abnormal findings on ... cancer, according to a new study published online ... the findings show that radiologist recommendations for additional ... to patient care. , RAIs, which have grown ...
Breaking Medicine News(10 mins):Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 2Health News:Physicians in China See Most Significant Demand for MabThera Biosimilar 3Health News:TalkLocal Launches in Henderson Weeks Following New Megafactory, New Jobs Announcement 2Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3
... , GAITHERSBURG, Md., Sept. 21 ... Services (HHS) has placed an order for an additional 29 million ... H1N1 influenza virus. This brings HHS orders to date to ... value of approximately $453 million. Previous HHS orders for approximately ...
... patients more likely to finish radiation course, study finds ... interrupted radiation treatment is a common problem among Medicare ... has found. , Researchers analyzed data from 5,086 Medicare ... and 2003 and found that nearly 40 percent of ...
... around the country, care is delayed, complicated and ... the same language. The situation is particularly dire ... York. Now, USC computer scientists, communication specialists ... robust and effective speech-to-speech (S2S) translation system for ...
... 2009 Results of a multicenter study in ... low rate of complications in diabetic patients, will be ... scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF). ... on Clinical and Angiographic Outcomes in Diabetic Patients: Multicenter ...
... put your waistline at risk, according to a new study ... how other peoples, weight and food choices influence how much ... concern," write authors Brent McFerran, Darren W. Dahl (both University ... Morales (Arizona State University). "We decided to investigate how someone,s ...
... , NEW YORK, Sept. 21 PricewaterhouseCoopers, ... explore the business implications of one of the greatest domestic policy ... As the debate continues to rage in Washington, health industry ... upcoming PwC webcast series entitled 360 Degree Insight will ...
Cached Medicine News:Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 2Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 3Health News:Head, Neck Cancer Treatment Often Not Completed 2Health News:'The doctor can understand you now' 2Health News:'The doctor can understand you now' 3Health News:Researchers find drug-eluting stents safe, effective for PCI in diabetics 2Health News:Watching your weight? Beware of skinny friends with big appetites 2Health News:PricewaterhouseCoopers Announces Five-part Webcast Series on the Business Implications of Health Reform (Regardless of the Final Bill) 2Health News:PricewaterhouseCoopers Announces Five-part Webcast Series on the Business Implications of Health Reform (Regardless of the Final Bill) 3Health News:PricewaterhouseCoopers Announces Five-part Webcast Series on the Business Implications of Health Reform (Regardless of the Final Bill) 4
Cytomegalovirus IgM ELISA....
Small Incision Microforceps: Tano ILM Forceps...
Blunt tipped forceps with a thin tip angled at approximately 135 and hollowed out "notch" on the interior of the distal end. Tip is shaped like a pic when in the closed position. For membrane peeling...
Microforceps: Claes ILM Forceps...
Medicine Products: